請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74476
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡孟勳 | |
dc.contributor.author | Yu-An Su | en |
dc.contributor.author | 蘇雨恩 | zh_TW |
dc.date.accessioned | 2021-06-17T08:37:58Z | - |
dc.date.available | 2019-08-19 | |
dc.date.copyright | 2019-08-19 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-08 | |
dc.identifier.citation | 1. Zhang, Y., Epidemiology of esophageal cancer. World J Gastroenterol, 2013. 19(34): p. 5598-606.
2. Enzinger, P.C. and R.J. Mayer, Esophageal cancer. N Engl J Med, 2003. 349(23): p. 2241-52. 3. Detterbeck, F.C., et al., The Eighth Edition Lung Cancer Stage Classification. Chest, 2017. 151(1): p. 193-203. 4. Ando, N., et al., Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 2000. 232(2): p. 225-32. 5. Sant, M., et al., EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann Oncol, 2003. 14 Suppl 5: p. v61-118. 6. Pennathur, A., et al., Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg, 2009. 87(4): p. 1048-54; discussion 1054-5. 7. Barbour, A.P., et al., Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol, 2010. 17(9): p. 2494-502. 8. Bosset, J.F., et al., Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med, 1997. 337(3): p. 161-7. 9. Walsh, T.N., et al., A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med, 1996. 335(7): p. 462-7. 10. Chen, P.C., et al., Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer. Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 1996-2003. 11. Akutsu, Y., et al., Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg, 2009. 33(5): p. 1002-9. 12. Sumpter, K., et al., Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer, 2005. 92(11): p. 1976-83. 13. Chaffer, C.L. and R.A. Weinberg, A perspective on cancer cell metastasis. Science, 2011. 331(6024): p. 1559-64. 14. Seyfried, T.N. and L.C. Huysentruyt, On the origin of cancer metastasis. Crit Rev Oncog, 2013. 18(1-2): p. 43-73. 15. Bacac, M. and I. Stamenkovic, Metastatic cancer cell. Annu Rev Pathol, 2008. 3: p. 221-47. 16. Duffy, M.J., P.M. McGowan, and W.M. Gallagher, Cancer invasion and metastasis: changing views. J Pathol, 2008. 214(3): p. 283-93. 17. Steeg, P.S., Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 2006. 12(8): p. 895-904. 18. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002. 2(6): p. 442-54. 19. Yokota, J., Tumor progression and metastasis. Carcinogenesis, 2000. 21(3): p. 497-503. 20. Frisch, S.M. and H. Francis, Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol, 1994. 124(4): p. 619-26. 21. Kim, Y.N., et al., Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol, 2012. 2012: p. 306879. 22. Gilmore, A.P., Anoikis. Cell Death Differ, 2005. 12 Suppl 2: p. 1473-7. 23. Simpson, C.D., K. Anyiwe, and A.D. Schimmer, Anoikis resistance and tumor metastasis. Cancer Lett, 2008. 272(2): p. 177-85. 24. Zhu, J.F., et al., MicroRNA-133b/EGFR axis regulates esophageal squamous cell carcinoma metastases by suppressing anoikis resistance and anchorage-independent growth. Cancer Cell Int, 2018. 18: p. 193. 25. Zhao, M.Y., et al., MiR-21 Suppresses Anoikis through Targeting PDCD4 and PTEN in Human Esophageal Adenocarcinoma. Curr Med Sci, 2018. 38(2): p. 245-251. 26. Friedman, R.C., et al., Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 2009. 19(1): p. 92-105. 27. Bartel, D.P., Metazoan MicroRNAs. Cell, 2018. 173(1): p. 20-51. 28. Pritchard, C.C., H.H. Cheng, and M. Tewari, MicroRNA profiling: approaches and considerations. Nat Rev Genet, 2012. 13(5): p. 358-69. 29. Shi, Y., et al., A ribosomal DNA-hosted microRNA regulates zebrafish embryonic angiogenesis. Angiogenesis, 2019. 30. Jin, Y., et al., Role of bta-miR-204 in the regulation of adipocyte proliferation, differentiation, and apoptosis. J Cell Physiol, 2019. 31. Shin, S., et al., Simultaneous Suppression of Multiple Programmed Cell Death Pathways by miRNA-105 in Cardiac Ischemic Injury. Mol Ther Nucleic Acids, 2019. 14: p. 438-449. 32. Li, B., et al., MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene, 2017. 36(28): p. 3986-4000. 33. Hur, K., et al., MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut, 2013. 62(9): p. 1315-26. 34. Derouet, M.F., G. Liu, and G.E. Darling, MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. PLoS One, 2014. 9(12): p. e115589. 35. van Rooij, E., The art of microRNA research. Circ Res, 2011. 108(2): p. 219-34. 36. O'Brien, J., et al., Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne), 2018. 9: p. 402. 37. Chendrimada, T.P., et al., TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature, 2005. 436(7051): p. 740-4. 38. Korpal, M., et al., The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem, 2008. 283(22): p. 14910-4. 39. Mak, C.S., et al., MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer, 2017. 16(1): p. 11. 40. Yu, S.J., et al., MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res, 2013. 19(6): p. 1389-99. 41. Zhang, L., X. Wang, and P. Chen, MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer, 2013. 13: p. 290. 42. Rojas, F., et al., The Oncogenic Response to MiR-335 Is Associated with Cell Surface Expression of Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP) Activity. PLoS One, 2015. 10(7): p. e0132026. 43. Lin, W.C., et al., miR-338-5p inhibits cell proliferation, colony formation, migration, and cisplatin resistance in esophageal squamous cancer cells by targeting FERMT2. Carcinogenesis, 2018. 44. Lei, D., et al., MiR-338-5p suppresses proliferation, migration, invasion, and promote apoptosis of glioblastoma cells by directly targeting EFEMP1. Biomed Pharmacother, 2017. 89: p. 957-965. 45. Zhao, Y., et al., The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther, 2018. 3: p. 3. 46. Izumoto, Y., et al., Hepatoma-derived growth factor belongs to a gene family in mice showing significant homology in the amino terminus. Biochem Biophys Res Commun, 1997. 238(1): p. 26-32. 47. Xiao, Q., et al., HDGF-related protein-3 is required for anchorage-independent survival and chemoresistance in hepatocellular carcinomas. Gut, 2013. 62(3): p. 440-51. 48. Nameki, N., et al., Solution structure of the PWWP domain of the hepatoma-derived growth factor family. Protein Sci, 2005. 14(3): p. 756-64. 49. Ge, Y.Z., et al., Chromatin targeting of de novo DNA methyltransferases by the PWWP domain. J Biol Chem, 2004. 279(24): p. 25447-54. 50. Wanschura, S., et al., Mapping of the gene encoding the human hepatoma-derived growth factor (HDGF) with homology to the high-mobility group (HMG)-1 protein to Xq25. Genomics, 1996. 32(2): p. 298-300. 51. Ikegame, K., et al., A new member of a hepatoma-derived growth factor gene family can translocate to the nucleus. Biochem Biophys Res Commun, 1999. 266(1): p. 81-7. 52. Everett, A.D., T. Stoops, and C.A. McNamara, Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem, 2001. 276(40): p. 37564-8. 53. Nakamura, H., et al., Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem, 1994. 269(40): p. 25143-9. 54. Oliver, J.A. and Q. Al-Awqati, An endothelial growth factor involved in rat renal development. J Clin Invest, 1998. 102(6): p. 1208-19. 55. Everett, A.D., et al., Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest, 2000. 105(5): p. 567-75. 56. Gao, K., et al., HDGF-related protein-2 (HRP-2) acts as an oncogene to promote cell growth in hepatocellular carcinoma. Biochem Biophys Res Commun, 2015. 458(4): p. 849-55. 57. Abouzied, M.M., et al., Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J, 2004. 378(Pt 1): p. 169-76. 58. El-Tahir, H.M., et al., Hepatoma-derived growth factor-related protein-3 interacts with microtubules and promotes neurite outgrowth in mouse cortical neurons. J Biol Chem, 2009. 284(17): p. 11637-51. 59. Dietz, F., et al., The family of hepatoma-derived growth factor proteins: characterization of a new member HRP-4 and classification of its subfamilies. Biochem J, 2002. 366(Pt 2): p. 491-500. 60. Shinohara, T., D.P. Singh, and N. Fatma, LEDGF, a survival factor, activates stress-related genes. Prog Retin Eye Res, 2002. 21(3): p. 341-58. 61. Bao, C.H., et al., Irradiated fibroblasts promote epithelial-mesenchymal transition and HDGF expression of esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 2015. 458(2): p. 441-7. 62. Abouzied, M.M., et al., Hepatoma-derived growth factor-related protein-3: a new neurotrophic and neurite outgrowth-promoting factor for cortical neurons. J Neurosci Res, 2010. 88(16): p. 3610-20. 63. Yun, H.S., et al., Knockdown of hepatoma-derived growth factor-related protein-3 induces apoptosis of H1299 cells via ROS-dependent and p53-independent NF-kappaB activation. Biochem Biophys Res Commun, 2014. 449(4): p. 471-6. 64. Yun, H.S., et al., Depletion of hepatoma-derived growth factor-related protein-3 induces apoptotic sensitization of radioresistant A549 cells via reactive oxygen species-dependent p53 activation. Biochem Biophys Res Commun, 2013. 439(3): p. 333-9. 65. Hamai, Y., et al., Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma. World J Surg, 2018. 42(7): p. 2190-2198. 66. Zhu, Z., et al., Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res, 2001. 61(4): p. 1707-16. 67. Wang, Y., et al., The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma. World J Surg Oncol, 2018. 16(1): p. 216. 68. Frisch, S.M., M. Schaller, and B. Cieply, Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci, 2013. 126(Pt 1): p. 21-9. 69. Lopes, A.B. and R.B. Fagundes, Esophageal squamous cell carcinoma - precursor lesions and early diagnosis. World J Gastrointest Endosc, 2012. 4(1): p. 9-16. 70. Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest, 2009. 119(6): p. 1420-8. 71. Li, G., K. Satyamoorthy, and M. Herlyn, N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res, 2001. 61(9): p. 3819-25. 72. Onder, T.T., et al., Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res, 2008. 68(10): p. 3645-54. 73. Derksen, P.W., et al., Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell, 2006. 10(5): p. 437-49. 74. Yang, J., et al., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 2004. 117(7): p. 927-39. 75. Desgrosellier, J.S. and D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 2010. 10(1): p. 9-22. 76. Uekita, T., et al., CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol, 2008. 172(6): p. 1729-39. 77. Liu, D.Z., et al., MiR-338 suppresses cell proliferation and invasion by targeting CTBP2 in glioma. Cancer Biomark, 2017. 20(3): p. 289-297. 78. Chu, C.A., et al., MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway. EBioMedicine, 2019. 43: p. 270-281. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74476 | - |
dc.description.abstract | 食道癌目前在全球是所有癌症中第七常見並且死亡率排名位居第六,現今較常治療的方法是化學放射療法。然而,能成功透過此方法治療的患者少於40%,更嚴重的是,有些患者經過化學放射治療後可能會促進癌症的復發。在我們實驗室先前的研究中,我們取了食道癌病患有復發及無復發的腫瘤樣本進行microRNA sequencing分析,結果顯示,miR-338-5p在有復發的病患中,和無復發的病患相比,具有顯著性的低表現量。先前研究更進一步證實過量表現miR-338-5p會抑制食道鱗狀癌細胞CE-81T的生長、遷移、菌落形成以及抗藥性。在本篇研究中,我們著重於研究miR-338-5p抑制CE-81T遷移能力的潛在機制。具有遷移能力的癌細胞可脫離胞外基質並且遷移至其他組織或器官形成續發腫瘤 (secondary tumor)。在癌細胞轉移的過程中,抵抗失巢凋亡 (Anoikis resistance) 是一個關鍵且必要的步驟。因此,根據本實驗室先前的研究,我們在本篇研究中推測miR-338-5p會藉由促進CE-81T失巢凋亡的能力來促成轉移能力降低的結果。
本篇研究中,失巢凋亡試驗 (Anoikis assay) 及軟性瓊膠群落生長試驗 (Soft agar assay) 分別被用於檢測miR-338-5p對於CE-81T失巢凋亡及非錨定依賴性生長 (anchorage-independent growth) 的影響。首先,結果顯示過量表現miR-338-5p可促進CE-81T進行失巢凋亡。為了瞭解哪一個基因是miR-338-5p的目標基因且參與在miR-338-5p對失巢凋亡的調控中,我們證實了HRP-3是miR-338-5p的目標基因且在失巢調控中此基因扮演重要的角色。為了更進一步了解miR-338-5p及HRP-3在失巢凋亡中的重要性,我們從CE-81T中篩選了具有抗失巢凋亡能力的細胞CE-81TAR (CE-81T anoikis resistance)。我們發現CE-81TAR相較於CE-81T,具有較好抵抗失巢凋亡的能力及非錨定依賴性生長能力。除此之外,結果顯示過量表現miR-338-5p及下調HRP-3表現量可降低CE-81TAR對於抵抗失巢凋亡及錨定依賴性生長能力。最後,下調HRP-3表現量,結果顯示CE-81T及CE-81TAR的細胞增殖率皆會下降。綜合以上結果,我們指出在食道鱗狀癌細胞CE-81T中,miR-338-5p會透過標的HRP-3來促進CE-81T失巢凋亡的能力,並進而抑制CE-81T遷移能力下降。 | zh_TW |
dc.description.abstract | Esophageal cancer (EC) is the 7th most common cancer and ranks 6th of mortality worldwide among all the other cancer types. Currently, the most common therapeutic strategy is concurrent chemoradiotherapy (CCRT). However, the respond rate of CCRT remains below 40%, and the other 60% patients may fail to this treatment. Worse than that, some patients may trigger disease progression after CCRT treatment. In our previous study, the tumor samples from EC patients with and without recurrence were performed by microRNA sequencing. The results showed that miR-338-5p was significantly down-regulated in the EC patients with recurrence. Moreover, the further study had shown that overexpressed miR-338-5p inhibited cell proliferation, migration, colony formation and drug resistance of esophageal squamous cell carcinoma CE-81T. In this study, we focused on the underlying mechanisms of inhibiting migration ability by miR-338-5p. Metastatic cells will detach from extracellular matrix and migrate to the other organs to form secondary tumor. Anoikis resistance is a critical step and required during metastasis. Based on our previous study, we hypothesized that miR-338-5p may promote anoikis and lead to decreasing metastatic ability of CE-81T.
In this study, anoikis and soft agar assays were performed to examine the effects of miR-338-5p on anoikis resistance in the CE-81T. The result showed that overexpression of miR-338-5p could increase anoikis in the CE-81T. To understand which genes may be the target of miR-338-5p and involved in regulation of anoikis, HRP-3 was validated as a target gene of miR-338-5p and play an important role in anoikis resistance. To further understand the importance of miR-338-5p and HRP-3 in regulation of anoikis, we generated anoikis resistant enriched subline (CE-81TAR) from adherent CE-81T. We found that CE-81TAR had more capacity of anoikis resistance and anchorage-independent growth than CE-81T. Moreover, overexpression of miR-338-5p and knockdown of HRP-3 could decrease anoikis resistance and anchorage-independent growth in CE-81TAR. Finally, knockdown of HRP-3 was shown to inhibit cell proliferation of CE-81T and CE-81TAR. Taken together, we indicated that miR-338-5p promoted anoikis by targeting HRP-3 and led to decreasing of migration in ESCC CE-81T. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:37:58Z (GMT). No. of bitstreams: 1 ntu-108-R06642009-1.pdf: 3991958 bytes, checksum: 0ef5b21ad62d147356ac432c238d5150 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 中文摘要 iii Abstract v Chapter 1 Introduction 1 1-1 Esophageal cancer 1 1-1-1 General introduction of esophageal cancer 1 1-1-2 Stages and therapy of esophageal cancer 2 1-1-3 Metastasis and anoikis 3 1-2 MicroRNAs (miRNAs) 4 1-2-1 Functions and biogenesis of miRNAs 4 1-2-2 Roles of miRNAs in cancer metastasis and anoikis resistance 6 1-2-3 Roles of miR-338-5p in cancers 7 1-3 Hepatoma-derived growth factor related protein family (HDGFRP) 7 1-3-1 Introduction of HDGFRP gamily 7 1-3-2 Roles of HRP-3 in cancer 9 1-4 Pilot study 10 Chapter 2 Research motivation and framework 12 Chapter 3 Materials and methods 14 3-1 Medium preparation 14 3-2 Cell lines and cell culture 14 3-3 MicroRNA transfection 15 3-4 Anoikis assay 15 3-5 Flow cytometry 15 3-6 Soft agar assay 15 3-7 Analyze RNA expression 16 3-8 Western blot analysis 17 3-9 Dual luciferase reporter assay 19 3-10 Plasmid construction 19 3-11 Lentivirus packing system 20 3-12 Characterizing anoikis-resistant cancer subline 22 3-13 MTT assay 23 3-14 Colony formation 23 3-15 Statistical analysis 24 Chapter 4 Results 25 4-1 miR-338-5p increased anoikis in CE-81T 25 4-2 HRP-3 is identified as a direct target gene of miR-338-5p 26 4-3 Knockdown HRP-3 increased anoikis and decreased anchorage-independent growth in CE-81T 27 4-4 CE-81TAR had greater capacity of anoikis resistance than CE-81T 28 4-5 Overexpression miR-338-5p and knockdown HRP-3 could decrease anoikis resistance and anchorage-independent growth in CE-81TAR 30 4-6 Knockdown of HRP-3 decreased cell proliferation in ESCC cells 31 Chapter 5 Conclusion 32 Chapter 6 Discussion 33 6-1 The regulation of miRNAs in anoikis and anchorage-independent growth of esophageal cancer 33 6-2 Gene differentiation in the CE-81TAR 34 6-3 The related genes of anoikis resistant cell during migration 35 6-4 The regulation of miRNAs in EMT proteins 37 6-5 The role of HRP-3 in anoikis resistant cell CE-81TAR 38 6-6 The effect of HRP-3 on proliferation in CE-81T and CE-81TAR 40 Chapter 7 Future works 42 Supplementary 65 References 66 | |
dc.language.iso | en | |
dc.title | miR-338-5p在食道鱗狀癌細胞中藉由標的HRP-3促進失巣凋亡 | zh_TW |
dc.title | miR-338-5p promotes anoikis in esophageal squamous cell carcinoma by targeting HRP-3 | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 莊曜宇,賴亮全 | |
dc.subject.keyword | 食道癌,細胞轉移,失?凋亡,CE-81T,miR-338-5p,HRP-3, | zh_TW |
dc.subject.keyword | Esophageal cancer,Metastasis,Anoikis resistance,CE-81T,miR-338-5p,HRP-3, | en |
dc.relation.page | 71 | |
dc.identifier.doi | 10.6342/NTU201902664 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-09 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 生物科技研究所 | zh_TW |
顯示於系所單位: | 生物科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。